Rex Eupseiphos, One does not have to try to be

New Post Public Reply Private Reply Replies (0) Message Board
TechGuru Rex Eupseiphos #35207
799
Rex Eupseiphos,

One does not have to try to be optimistic based on anecdotal data. We can use the data we all have (from different perspectives) to form an opinion. We are all doing it. When Dr. NP says “this is a double digit stock”, or Dr. Lalezari says” this drug will be approved” or Dr. Patterson says” I am seeing extraordinary results” they have formed an opinion and are communicating it. They are not trying to be optimistic.

They are and so am I. The data is sometimes anecdotal, sometimes is not.

Quote:
but it's really hard to make an even slightly compelling statistical case for how these forecast the results of the trials


Not to beat a dead horse here but I respectfully disagree. There is a case and is statistically valid in the sense of modeling with the information at hand a possible outcome. Something is better than nothing. Of course, we would like to have more data and, of course, we would like to have the perfect control group. The problems is: we don’t. If we wait until the trial is over to have all the information perhaps will be too late (for investment purposes).

Quote:
Small convenience sample, no control group. When you don't have good samples, statistical formulas are more misleading than informative because they give an unrealistic semblance of certainty when there is nothing there


Once again, I disagree with you. First of all, nobody is saying there is certainty, by the contrary. As a matter of fact, even a p-number of 0.05, normally used by FDA as level of significance, has uncertainty. The board readers are educated investors and the idea is to provide information. No more no less. Everybody is free to use it as is. Nobody is claiming to know the truth here nor communicating certainties (or uncertainties).

One patient working out of a ventilator is not a good statistical sample, neither there is a "control", however it provides lots of information. We all know that it does not provide certainty but we all agree that there is something "there".

Quote:
Your simple little calculations are fine, and I do that sort of thing all the time. But I recognize that the numbers that come out the other side are little more than speculation and are guaranteed to be wrong.


I hope you are not saying this in a demeaning way. But, my calculations are not simple as they are not complicated either (they use the same model that likely FDA will use (Binomial for Severe to Critical) and, for the case of the simulations of Mild-to-Moderate, un-weighted normal distribution. They are “little” simply because I don’t have more data, I wish we had it. As for the results, I am sure everybody knows these are just approximations and that is why every time we work with several possibilities (in the example naming several outcomes as for the number of survivals).

In regards to the “control group” and the 88% number mentioned in the Patterson paper (from the Richardson paper). Sure, It can be higher of lower. However, it is a valid to say: if this number is valid, and, taking into account that this many patients treated with Leronlimab survived. Does this provide evidence that the drug was beneficial ? Yes? No ?. Now if this is, say 50%, is this still the case? Yes ? No?. And so on. I find it useful to ask and answer these questions to decide on my investment(s).

And hope some of the board feel likewise.

Quote:
A few months ago, I thought the chances of SP going to 0 were about the same as the chances of going to $10


I have been investing in CYDY for many years, have been buying stock all the way to the $0.30’s as, after reading several papers on the science of CCR5 I was then, as I am now, convinced that the chances of CYDY going to $0 was, well 0.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Texas Plumbing Award Signals Local Service Discipline

Updated Category News Views 90

A clogged main line is not glamorous, but it is where a local service reputation gets tested for real. Neighborhood Plumbing and Drain has been named a 2026 Best of Texas Award winner in the Plumbing Contractors category, a recognition that matters less as a trophy than as a public signal: customers around Central Texas have noticed the outfit. For anyone watching the...

Continue Reading
Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 106

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 9

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Point72 Breach Puts Cyber Controls Under the Microscope

Updated Category News Views 76

Two compromised user accounts can turn a supposedly contained cyber problem into a boardroom headache in a hurry. Point72 Asset Management, the global alternative-investment firm founded by Steven A. Cohen in 2014, has reported a social-engineering incident involving accounts that were used to copy files from limited portions of its IT systems. This is not a trading-loss...

Continue Reading
Rox Taps Dynamics 365 Without Forcing a CRM Reset Yet

Updated Category News Views 189

Enterprise software buyers hate renovations when a useful extension will do. Rox’s new integration with Microsoft Dynamics 365 Sales, announced November 19, 2026, is built around that unglamorous but very real fact. The company is not asking a Global 2000 sales organization to rip out its customer system, retrain everybody, and pray an AI layer somehow pays for the...

Continue Reading
Carnival Maps a Longer, Broader Bet on Cruise Demand

Updated Category News Views 36

A cruise operator does not order ships for 2035 because it is feeling timid. Carnival is laying out a long runway of hardware, private-destination capacity and onboard-to-onshore spending hooks, all aimed at keeping guests inside its ecosystem longer. For NYSE:CCL, this is not a next-quarter story. It is a very public statement that management sees enduring appetite for...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 57

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading
Candel’s BLA Delay Puts Disclosure Timing Under Fire

Updated Category News Views 118

A December filing turned into a mid-2027 wait, and Candel shareholders absorbed the damage in one ugly trading session. On November 13, shares of Candel Therapeutics fell 26% after the company disclosed that its biologics license application, or BLA, for aglatimagene in prostate cancer was no longer expected in December 2026. The revised plan is to submit in the middle of...

Continue Reading
EmTech AI 2027 Puts AI Ambitions Through Reality Test

Updated Category News Views 111

A three-day gathering cannot settle AI's biggest arguments, but MIT Technology Review has picked the right fight for EmTech AI 2027: make the industry face a Reality Test. The conference runs May 11–13, 2027, at MIT's campus and online, and that theme lands because the AI conversation has spent plenty of time admiring the engine while skipping the ugly maintenance bill....

Continue Reading
Winter Leaks Can Lock In Tarrant Sewer Costs for 2027

Updated Category News Views 133

Silent toilet seepage has a nasty habit of turning winter into a twelve-month utility hangover. Tarrant County homeowners are heading into the period when some local cities use household water consumption to calculate residential sewer charges for the following year. That is not the sort of detail anybody enjoys thinking about during the holidays, but ignoring it can be...

Continue Reading

Top 5 Most Recently Viewed Articles

Euroseas Ltd. Achieves Strong Financial Results and Growth

Updated Category News Views 141

Overview of Euroseas Ltd. Euroseas Ltd. operates as a leader in the container shipping sector, primarily focused on providing efficient seaborne transportation for containerized cargo. The company has established a strong reputation for operational excellence and commitment to sustainable practices within its fleet management. Financial Performance Highlights In a recent...

Continue Reading
Market Dynamics Shifting with Focus on Inflation Trends

Updated Category News Views 180

Market Performance and Economic Insights As we dive into today's economic landscape, U.S. stocks have reached new heights while the effects of a recent hurricane are fading. With key inflation data set to be released soon, analysts are closely monitoring market responses and the implications for future Federal Reserve policy. The recent performance of U.S. stocks...

Continue Reading
Strategic Moves: Nordson EVP Acquires Over $250K in Stock

Updated Category News Views 214

Nordson EVP Makes Significant Stock Investment Recently, a notable movement was observed in the stock holdings of Nordson, specifically by its Executive Vice President, Daniel Roy Hopgood. According to a recent SEC filing, Hopgood made a considerable insider purchase worth $251,885, acquiring 1,201 shares of Nordson. Insights into the Insider Transaction This transaction,...

Continue Reading
Rising Pet Poisoning Calls Due to Antidepressants and ADHD Drugs

Updated Category News Views 102

Back between 2019 and 2022, we saw an insane rise in calls to pet poison hotlines—an 84.9% spike related to antidepressants and antianxiety drugs. You know that’s serious business when folks are dialing in about their furry friends getting into the pills meant for human mental health. The numbers don’t lie; as people got more open about mental health issues, it...

Continue Reading
Humacyte, Inc. Investors: Class Action Lawsuit Update

Updated Category News Views 330

Understanding the Class Action Lawsuit Against Humacyte, Inc. Many investors are becoming increasingly aware of the class action lawsuit against Humacyte, Inc. (NASDAQ: HUMA). The firm leading this charge, Pomerantz LLP, has filed this significant case to address potential securities fraud related to the company's operations and communications. This legal action has...

Continue Reading